Sign in to view content

Time to Dry Analysis of Brolucizumab Versus Aflibercept in Patients With Neovascular AMD: 96-Week Data From HAWK and HARRIER Trials

Carl D. Regillo, MD

Video
Published 2019

Carl D. Regillo, MD, FACS

AMD Neovascular Part I

Related

Are There Safety Concerns With Bevacizumab for ROP
Robert L. Avery, MD
Updates from the Field
2017
Randomized Trial of Initiating Therapy With Aflibercept, Laser, or Observation for Eyes With Good Vision and Center-Involved DME
Carl W. Baker, MD, FASRS
Annual Meeting Talks
2019
Evaluation of 8 mg Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration: Results from the Phase 2 CANDELA Study
W. Lloyd Clark, MD, FASRS
Updates from the Field
2022

Category: AMD-Neovascular

See more